Genipin and UV-CLX is safe and effective for keratoconus

Article

Genipin and UV-riboflavin crosslinking (UV-CLX) is a safe and effective procedure for keratoconus

Genipin and UV-riboflavin crosslinking (UV-CLX) is a safe and effective procedure for keratoconus, claims a study in Molecular Vision.

Dr Marcel Y. Avila et al., Department of Ophthalmology, Facultad de Medicina, Universidad Nacional de Colombia, Bogota, Colombia, separated porcine eyes into three groups comprising genipin 0.25% UV-CLX (clinical crosslinking procedure), a glutaraldehyde 0.1% (gold standard crosslinker) and control.

A pressure sensor cannulated to the anterior chamber continuously monitored all groups. Changes in ocular pressure due to ocular volume were evaluated. The exponential of polynomial quadratic fit was used to calculate ocular rigidity. A viability assay with alizarin red staining was used to assess endothelial damage.

In the genpin and UV-CLX globes where the cornea was stiffened there were significant changes in IOP. Mean ocular rigidity coefficient was 0.0078 mmHg/μL for genpin, 0.0065 mmHg/μL for UV-CLX, 0.0092 mmHg/μL for glutaraldehide and 0.0046 mmHg/μL for control eyes.

In the control group endothelial damage was 5.9±1.8%, 10.3±1.7% in UV-CLX, 9.4±1.5% in Genipin 0.25% and 40.1±6.2% in glutaraldehide. In the UV-CLX group there was a significant reduction of keratocites.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.